A Study Assessing the Safety and Effectiveness of Ultra-Hypofractionated Radiation Therapy after Brachytherapy for Localized Intermediate-Risk Prostate Cancer

Full Title

Ultra-hypofractionated, Image-guided, Intensity-modulated Radiation Therapy in Combination with Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer

Purpose

Brachytherapy is a form of radiation therapy where radioactive sources are implanted in cancerous tissue to kill cancer cells. For men with prostate cancer, brachytherapy may be followed by external beam radiation therapy delivered five days a week for up to five weeks. In this study, researchers want to see if giving higher doses of image-guided intensity-modulated radiation therapy less often (every other day for five days over two weeks) after brachytherapy instead of conventional radiation after brachytherapy is safe and effective. This higher-dose, less frequent radiation therapy is called “hypofractionated radiation therapy.”

Image-guided intensity-modulated radiation therapy is give very precisely, limiting exposure to healthy tissues. Hypofractionated radiation therapy is more convenient for patients because they don’t have to come in for treatment as often.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have localized prostate cancer that has an intermediate risk of coming back after therapy.
  • Patients may not have had prior prostate surgery, chronic prostatitis, urethral stricture, inflammatory bowel disease, or radiation therapy to the pelvis.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Marisa Kollmeier at 212-639-3952.

Protocol

14-193

Phase

II

Disease Status

Newly Diagnosed

Investigator